HLA-matched PT/CY

JRCT ID: jRCTs031180140

Registered date:20/02/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: AML, ALL, NHL, MDS
• Date of first enrollment: 20/02/2019
• Target sample size: 20
• Study type: Interventional
• Intervention(s): 50 mg/kg of cyclophosphamide on day 3, 4

Outcome(s)

• Primary Outcome: Success rate at 6 months.

Secondary Outcome

engraftment
acute GVHD (grade 2-)
chronic GVHD
non-relapse mortality

Key inclusion & exclusion criteria

• Age minimum: >= 16age old
• Age maximum: <= 60age old
• Gender: Both

Include criteria

1) AML, ALL, NHL, MDS
2) age 16-60
3) possessing allele 8/8 matched donor (age 16-60)
4) PS =< 2
5) EF >= 40%
6) SpO2 >= 90%
7) %VC >= 70% and FEV1.0% >= 70%
8) Bil =< 2.0 mg/dl
9) Ccr >= 30 ml/min

Exclude criteria

1) positive for HBs Ag
2) positive for HIV Ab
3) depression
4) pregnancy
5) coexisting active cancer
6) active infection
7) pentostatin administration
8) hypersensitivity to cyclophosphamide

Related Information

• Primary Sponsor: Chiba Shigeru
• Secondary Sponsor: University of Tsukuba Hospital